Preclinical investigation of palbociclib, a selective CDK4/6 inhibitor (Figure 2), present a strong rationale for clinical studies to test the combination of palbociclib with fulvestrant in HR+/HER2− BC patients. Here, CDK4 is linked to breast cancer.